Braeburn

What Braeburn does

Braeburn Inc. is a U.S.-based specialty pharmaceutical company headquartered at 450 Plymouth Rd #400, Plymouth Meeting, Pennsylvania, focused exclusively on the treatment of opioid use disorder (OUD). Founded in 2012, the company develops, manufactures, and commercializes BRIXADI (buprenorphine) extended-release injection for subcutaneous use, available in weekly and monthly formulations (CIII). The proprietary extended-release injection platform, identified during development as CAM2038, sustains buprenorphine plasma levels above 0.5 ng/mL, suppressing opioid withdrawal following a single dose. Clinical evidence supporting BRIXADI includes retrospective cohort data showing 20.4% vs 7.2% six-month treatment retention versus sublingual buprenorphine (P<0.001), post-hoc analyses covering up to 30,038 patients in fentanyl-using populations, and the NIH-funded MOMs Study demonstrating 82.5% vs 72.6% illicit opioid abstinence during pregnancy (p=0.009), published in JAMA Internal Medicine in 2026-03.

The company monetizes BRIXADI through prescription pharmaceutical sales distributed via a dedicated direct sales force targeting physicians, nurse practitioners, physician assistants, pharmacists, and addiction specialists who treat OUD. Specialty pharmaceutical channels — including PBMs, insurers, and government programs — handle reimbursement, while Braeburn operates the Braeburn By Your Side patient support program (877-279-7367) and a medical information line (833-274-9234) to support adherence and clinical inquiries. Pricing is not publicly disclosed. The company supplements its commercial motion with medical conference presence (CPDD, ASCP), medical science liaisons, the Rise for Recovery Advocacy Summit, the Reframe & Reclaim docuseries, and GTM partnerships with Shatterproof, Savage Sisters, Mobilize Recovery, and other community-based recovery organizations.

Operationally, Braeburn employs 101–250 staff across functions led by President & CEO and founder Mike Derkacz, alongside CMO Joshua Cohen (MD, MPH), CFO Louis Ricigliano, CCO Paul Johnson, Chief Compliance Officer Meredith Taylor, General Counsel Brian Hirsch, and VP of Manufacturing Operations Judy Cohen. The company has raised approximately $133M in disclosed private financing, including a $110M round in January 2018 led by Wellington Capital Management with participation from Apple Tree Partners, Avista Healthcare Partners, Deerfield Capital Management, New Leaf Venture Partners, RA Capital Management, and Rock Springs Capital. The company is privately held, Delaware-incorporated, and restricted by its Terms of Use to U.S. residents, with an Investigator-Initiated Trial Program and a business development search for additional rare-disease and high-unmet-need assets.

Name

Braeburn

Legal name

Braeburn Inc.

Website

https://braeburnrx.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

101–250 employees

Short description

Braeburn is a U.S. specialty pharmaceutical company that develops and commercializes BRIXADI, an FDA-approved extended-release buprenorphine injection in weekly and monthly formulations for opioid use disorder, serving patients, healthcare providers, and pregnant and postpartum women with OUD.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals / Opioid Use Disorder Treatment

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges) (CRADAMAD)

Keywords

• Extended-release buprenorphine
• Opioid use disorder treatment
• Addiction medicine pharmaceuticals
• Long-acting injectable therapy
• Specialty pharmaceutical products

Headquarters

HQ city

Plymouth Meeting

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Marketing or Sales, Technology or R&D, Operations

Revenue model

1. Pharmaceutical Product Sales: Braeburn generates revenue through the sale of its FDA-approved prescription medication BRIXADI (buprenorphine) extended-release injection. The product is available in weekly and monthly formulations for subcutaneous use in treating opioid use disorder. As a specialty pharmaceutical company, revenue is derived from product sales to healthcare providers and pharmacies.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

Braeburn develops and commercializes BRIXADI (buprenorphine) extended-release injection for subcutaneous use (CIII), available in weekly and monthly formulations, as a medication for the treatment of opioid use disorder (OUD). The company operates as a specialty pharmaceutical firm, generating revenue primarily through product sales to healthcare providers and pharmacies, supported by a patient support program (Braeburn By Your Side) and medical information services.

Product overview

Braeburn is a pharmaceutical company with a single core product: BRIXADI (buprenorphine) extended-release injection. BRIXADI is available in two formulations—weekly and monthly—providing flexible dosing options for patients with opioid use disorder. The company focuses exclusively on this medication, which is the primary therapeutic offering in their portfolio for treating opioid use disorder.

Differentiator

Problem solved

Functional benefit

Brands

• BRIXADI: BRIXADI (buprenorphine) extended-release injection for subcutaneous use, a medication for opioid use disorder available in weekly and monthly formulations.

Products and services

• BRIXADI Weekly (buprenorphine) Extended-Release Injection Extended-release buprenorphine injection administered weekly via subcutaneous route for the treatment of opioid use disorder in adults. The only FDA-approved extended-release buprenorphine with clinical trial evidence studied in pregnant and postpartum women (NIH-funded MOMs Study).
• BRIXADI Monthly (buprenorphine) Extended-Release Injection Extended-release buprenorphine injection administered monthly via subcutaneous route for the treatment of opioid use disorder in adults. Provides sustained plasma concentrations that suppress opioid withdrawal and reduces the burden of daily sublingual dosing.

Quantifiable outcome

• 20.4% vs 7.2% 6-month treatment retention rate superiority for BRIXADI vs sublingual buprenorphine (P<0.001)
• +2 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• ShatterproofcoreGTM or Marketing PartnerNational nonprofit dedicated to transforming addiction treatment in the U.S. Braeburn sponsors Shatterproof Walks in Boston, Chicago, and NYC. Partnership focuses on ending stigma of addiction and supporting individuals/families affected by OUD.
• Savage SisterscoreGTM or Marketing PartnerGrassroots harm reduction and recovery organization in Philadelphia providing trauma-informed recovery homes, public health outreach, and education. Founded by Adam Al-Asad's sister Sarah after her recovery. Braeburn is a significant supporter.
• The Everywhere ProjectminorGTM or Marketing PartnerOrganization expanding access to harm reduction education and resources for overdose prevention across the Philadelphia region while reducing stigma against people who use drugs.
• Nexus Recovery CenterminorGTM or Marketing PartnerCommunity of hope and recovery for women offering residential treatment, intensive outpatient, medical detoxification, medications for OUD, psychiatric services, and peer support services.
• Foundation for RecoveryminorGTM or Marketing PartnerNevada's statewide Recovery Community Organization providing peer recovery support, employment, transportation, and housing programs for individuals and families affected by addiction.
• Mobilize RecoverycoreGTM or Marketing PartnerBraeburn sponsors Mobilize Recovery Across America bus tour, a cross-country initiative during National Addiction and Mental Health Recovery Month. Collaboration supports celebrating recovery and advocacy efforts across the country.
• Pharmaceutical Product PartnersminorStrategic or Co-development PartnerBraeburn seeks partnerships to bring medicines or medical devices to U.S. patients, looking for new assets that address high unmet need in rare or greatly underserved markets.
• Investigator-Initiated Trial PartnersminorStrategic or Co-development PartnerBraeburn supports investigator-initiated research through its IIT Program, providing funding and/or medicinal product for proposals exploring long-acting injectable buprenorphine in underserved settings and populations.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Indivior: Indivior markets Sublocade, the first FDA-approved monthly extended-release buprenorphine injection for OUD. It is the closest direct competitor to Braeburn's BRIXADI in product format, prescriber base, and patient population.
• Camurus: Camurus developed the FluidCrystal technology underlying BRIXADI (originally CAM2038) and markets Buvidal, a weekly/monthly extended-release buprenorphine injection, in Europe and Australia. It is the most direct technology and product peer to Braeburn in the global ER-buprenorphine category.
• Alkermes: Alkermes markets Vivitrol, a monthly extended-release naltrexone injection approved for both OUD and alcohol use disorder. Vivitrol competes for the same prescribers, patients, and value-based contracts as BRIXADI in the long-acting injectable MOUD market.
• US WorldMeds: US WorldMeds markets Lucemyra (lofexidine), an FDA-approved non-opioid treatment for mitigation of opioid withdrawal symptoms. It addresses an adjacent step in the OUD treatment journey and targets the same prescriber audience as Braeburn.

Emerging players

• Emergent BioSolutions: Through its acquisition of Adapt Pharma, Emergent markets Narcan (naloxone) nasal spray, the leading opioid overdose reversal product. Narcan operates in the same OUD ecosystem as BRIXADI, addressing the public-health crisis Braeburn targets.

Broad incumbents

• Mallinckrodt Pharmaceuticals: Mallinckrodt has historically been a major player in OUD and pain treatment (including generic buprenorphine products) and is a broad specialty pharma incumbent. It competes in adjacent generics and branded specialty CNS markets relevant to Braeburn's commercial environment.
• Otsuka Pharmaceutical: Otsuka is a large CNS-focused pharmaceutical company with mental health and addiction-adjacent assets (e.g., Abilify franchise) and pursues specialty indications overlapping Braeburn's prescriber and advocacy ecosystem.
• Teva Pharmaceutical Industries: Teva markets generic sublingual buprenorphine products and previously employed Braeburn's CEO. As the dominant generic buprenorphine supplier, Teva sets the pricing baseline Braeburn must justify clinically to drive branded switching.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/braeburnrx
• YouTubeyoutube.com/@BraeburnRx
• LinkedInlinkedin.com/company/braeburn
• Instagraminstagram.com/braeburnrx

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds2 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Braeburn